Pseudoephedrine
| Evidence Level: L2 | Predicted Indications: 3 |
Table of Contents
Pseudoephedrine: From Nasal Decongestant Use to Nasal Cavity Disease
One-Sentence Summary
Pseudoephedrine is an oral alpha-adrenergic agonist long used worldwide as a nasal decongestant, though it currently holds no marketing authorization in India. The TxGNN model assigns its highest prediction score to Nasal Cavity Disease, but the supporting evidence indicates this largely reflects the drug’s well-established core pharmacology rather than a novel repurposing signal, with 19 clinical trials and 7 publications identified in the evidence pack.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not formally recorded (drug not marketed in India); internationally known as an oral nasal decongestant |
| Predicted New Indication | Nasal Cavity Disease |
| TxGNN Prediction Score | 99.75% |
| Evidence Level | L2 |
| India Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed formal mechanism-of-action documentation (DrugBank MOA field) is currently a data gap. However, the evidence pack’s repurposing rationale describes pseudoephedrine as a classic α-adrenergic agonist that indirectly promotes norepinephrine release, acting on α1-receptors in nasal mucosal vascular smooth muscle to produce vasoconstriction and reduce mucosal congestion and swelling.
This is worth flagging directly: the analysis in the evidence pack itself notes that this α1-adrenergic decongestant action is textbook-level, well-established pharmacology for pseudoephedrine — not a newly discovered mechanistic link. TxGNN’s very high score (99.75%) for “Nasal Cavity Disease” is therefore best read as the model correctly recovering a known drug-disease relationship rather than surfacing a novel repurposing hypothesis.
That said, because pseudoephedrine has no current marketing authorization in India, formal recognition of this indication would still represent a genuine regulatory gap to close, even though the underlying pharmacology is not new. Supporting clinical evidence (e.g., a Phase 2 trial directly comparing pseudoephedrine to placebo in allergic rhinitis) is consistent with this established decongestant role.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00804687 | Phase 2 | Completed | 53 | Randomized, double-dummy, placebo-controlled crossover directly comparing JNJ-39220675 and pseudoephedrine for allergic rhinitis in an environmental exposure chamber |
| NCT00562120 | Phase 2 | Completed | 21 | H3-receptor antagonist tested against nasal allergen challenge; acoustic rhinometry used to measure congestion, the same endpoint model used for decongestant efficacy |
| NCT03620513 | Phase 4 | Completed | 160 | Evaluated topical anesthesia and/or decongestant pretreatment for reducing discomfort during fiberoptic nasal pharyngoscopy/laryngoscopy |
Note: 16 additional registered trials returned for this indication (e.g., endoscopic sinus surgery, balloon sinuplasty, nasal spray devices, probiotics) were excluded as they evaluate surgical, device, or unrelated-drug interventions rather than pseudoephedrine itself.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 11345158 | 2001 | Cohort | American Journal of Rhinology | Direct comparison of oral/topical decongestant effects of phenylpropanolamine and d-pseudoephedrine using acoustic rhinometry |
| 22794679 | 2012 | Review | Allergy and Asthma Proceedings | Overview of nonallergic rhinitis subtypes and their shared congestion/rhinorrhea symptomatology |
| 19769798 | 2009 | Other (animal model) | American Journal of Rhinology & Allergy | Feline model showing decongestant effects of D-pseudoephedrine alone and combined with desloratadine |
| 24492651 | 2014 | Other (animal model) | J Pharmacol Exp Ther | Pharmacological evaluation of α2c-adrenergic agonists in animal models of nasal congestion (mechanistic comparator class) |
| 12387934 | 2002 | Other (animal model) | J Pharmacol Toxicol Methods | Development of a chronic dog model for characterizing nasal decongestant drug mechanisms |
| 11895194 | 2002 | Other (animal model) | American Journal of Rhinology | Acoustic rhinometry validated in a dog model of nasal congestion via mast cell degranulation |
| 12962193 | 2003 | Other (animal model) | American Journal of Rhinology | Ragweed-sensitized dog model of allergic nasal congestion using acoustic rhinometry |
India Market Information
Pseudoephedrine currently holds no marketing authorization in India (0 registered products; market status: Not Marketed). No license records are available for review.
Safety Considerations
Drug Interactions: 150 documented interactions on record. Of the sample reviewed, the large majority are Moderate-severity interactions with antidiabetic agents — including insulins (human, aspart, degludec), sulfonylureas (glimepiride, glipizide, glyburide, chlorpropamide, acetohexamide), GLP-1 receptor agonists (albiglutide, dulaglutide, exenatide), SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin), alogliptin, and acarbose — consistent with pseudoephedrine’s sympathomimetic effect counteracting glycemic control. One Minor interaction was noted with ascorbic acid.
Detailed prescribing warnings and contraindications are not currently available in this evidence pack; please refer to the package insert for that information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The top-ranked prediction (Nasal Cavity Disease) is supported by a completed Phase 2 RCT directly involving pseudoephedrine and corroborating decongestant-mechanism literature (L2), but the evidence pack itself flags that this reflects known pharmacology rather than a novel signal. Two lower-ranked candidates — acute laryngopharyngitis (L5, Hold, no clinical or literature evidence) and allergic urticaria (L4, Hold, mechanistically weak link) — do not currently meet the bar to proceed.
To proceed, the following is needed:
- Formal mechanism-of-action (MOA) documentation from DrugBank (currently a data gap, DG002)
- Package insert warnings/contraindications, particularly given the extensive antidiabetic drug interaction profile (currently a Blocking data gap, DG001)
- Clarification on whether “Nasal Cavity Disease” is intended as a new India regulatory indication or simply confirmation of existing decongestant use, since no original indication is currently on file for India
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.